Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $245,803.74 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CEO Grant Pickering sold 2,366 shares of Vaxcyte stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total transaction of $245,803.74. Following the transaction, the chief executive officer now directly owns 137,398 shares in the company, valued at $14,274,278.22. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Grant Pickering also recently made the following trade(s):

• On Friday, November 1st, Grant Pickering sold 15,000 shares of Vaxcyte stock. The shares were sold at an average price of $106.82, for a total transaction of $1,602,300.00.
• On Monday, October 7th, Grant Pickering sold 7,098 shares of Vaxcyte stock. The stock was sold at an average price of $109.21, for a total transaction of $775,172.58.
• On Friday, August 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $78.98, for a total transaction of $1,184,700.00.

Vaxcyte Stock Performance

Shares of PCVX traded up $3.97 during trading hours on Friday, reaching $106.67. 1,014,877 shares of the company's stock traded hands, compared to its average volume of 840,864. The firm's 50 day simple moving average is $111.04 and its 200-day simple moving average is $86.92. Vaxcyte, Inc. has a 12 month low of $46.16 and a 12 month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the prior year, the company posted ($0.91) earnings per share. As a group, equities analysts forecast that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Riverview Trust Co bought a new position in shares of Vaxcyte during the third quarter valued at $27,000. Blue Trust Inc. increased its stake in Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after acquiring an additional 93 shares during the last quarter. Fifth Third Bancorp bought a new position in shares of Vaxcyte during the 2nd quarter valued at approximately $35,000. J.Safra Asset Management Corp boosted its holdings in Vaxcyte by 649.4% during the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock valued at $46,000 after acquiring an additional 526 shares during the period. Finally, Meeder Asset Management Inc. boosted its holdings in Vaxcyte by 1,007.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock valued at $80,000 after acquiring an additional 635 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PCVX has been the topic of several research reports. Bank of America upped their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. Mizuho upped their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research note on Tuesday, September 10th. Needham & Company LLC reissued a "buy" rating and set a $140.00 target price on shares of Vaxcyte in a research report on Wednesday. Leerink Partners raised their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 3rd. Finally, BTIG Research increased their target price on Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.